Ren Life Sciences closes €375M Fund II above hard cap in four weeks
What's the deal? Specialist European investment firm Ren Life SciencesDealroom has a profile for this one. Try Dealroom → has closed its second fund, Ren Life Sciences Partners II, oversubscribed at €375 million (roughly $411 million). The fund exceeded its €300 million target and €350 million hard cap in just over four weeks from launch.
Why now? Ren launched the fund in July 2026 and reached its final close by September, an unusually fast turnaround for a private markets raise. Pacenote CapitalDealroom has a profile for this one. Try Dealroom → acted as exclusive placement agent.
What's the endgame? Ren invests in high-growth biotech and life-sciences companies with strong scientific foundations and clinical potential. It aims to speed patient impact and support high-quality jobs across European life sciences.
The details: The fund is domiciled in Guernsey under its Private Investment Fund regime. Langham HallDealroom has a profile for this one. Try Dealroom → provided fund administration from its Guernsey office, and Carey OlsenDealroom has a profile for this one. Try Dealroom → acted as Guernsey legal counsel alongside fund counsel Paul, Weiss, Rifkind, Wharton & GarrisonDealroom has a profile for this one. Try Dealroom →.
"The speed and scale of the fundraising reflects the confidence investors have in Ren's strategy and leadership team," said Ian Smith, director at Langham Hall.
The signal: The rapid, oversubscribed close points to strong investor appetite for specialist life-sciences strategies, even as capital tilts toward larger, later-stage biotech rounds. It arrives alongside major European peer raises — Forbion's €2.3 billion across two funds and Sofinnova's €725 million crossover fund — though those are far larger platforms than Ren's.
Read more: careyolsen.com
Image credit: Generated with Gemini